Biomarker Testing Patterns And Use Of Targeted Therapy In Medicare Fee-For-Service (Ffs) Beneficiaries Newly Diagnosed With Metastatic Non-Small Cell Lung Cancer (Mnsclc).

Anik Patel,Aurelien Jamotte,Tara Matsuda,Partha Manas Das, Ehab Elkhouly,Ann Xi,Barton Jones,Anne Murunga,Allison Petrilla,Nathan Markward,Kendall Lee Stevinson

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览4

暂无评分

摘要

278Background: The number of targeted therapies approved for treatment of mNSCLC has increased over the past 5 years. Strategies to identify eligible patients with actionable mutations for targeted...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要